Transgene completes randomisation in phase 2 trial of tg4050
Company expects two‑year dfs data by q1 2028
Read More
Author: John Pinching
Bayer wins MHRA approval for Kerendia in heart failure
New authorisation offers additional option for patients with lvef ≥40%
Read More
Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
Partnership to develop next‑generation T‑cell engagers for solid tumours
Read More
Kainova expands DT 7012 trial into Europe
First patient dosed as DOMISOL study grows beyond Australia
Read More
Paul Edwards
Ardena has appointed Paul Edwards as Chief People Officer
Read More- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
